Vodis Pharmaceuticals, Inc. (VP)

logoIn Canada, Vodis Pharmaceuticals, Inc is considered a foremost brand name of medical marijuana. The company prides in its award-winning grow teams and is currently waiting to be inspected by Health Canada for its marijuana license under new regulations. It has also very recently formed a subsidiary in the US to enter its marijuana market through Washington State.

Vodis Pharmaceuticals’ product line comprises of 25 strains of medicinal marijuana, grouped into the Indica, Sativa, and Hybrid groups. These products are handled by the subsidiary Vodis Innovative Pharmaceuticals, Inc, which sells them through its website (though its selling is currently halted as the company awaits inspection).

Once Vodis Pharmaceuticals obtains its license under Canada’s Marihuana for Medical Purposes Regulations (MMPR), it will begin producing between 150 to 200 pounds of medical cannabis per month. Production will be at its 12,000-square foot facility in Canada.

On October 2, 2014, Vodis announced that it has formed its wholly owned subsidiary Vodis USA, Inc, based in Washington State. The subsidiary’s primary aim is to develop real estate in the area to serve licensed businesses that produce and process “I-502 marijuana”. Aside from providing such facilities, Vodis will also license its growing techniques, manufacturing processes, and standard operating procedures.

Vodis Pharmaceuticals, Inc started out in 2011 as Southbridge Resources Corp, a company that explored mineral properties in British Columbia. It became Vodis Pharmaceuticals, Inc in early 2014, just as it had acquired it subsidiary Vodis Innovative Pharmaceuticals.

Today, Vodis is listed in the Canadian Securities Exchange as VP, with a market cap of CAD 18.93 M. Its management team is comprised of Otto Folprecht, CEO; Ivan Millovski, President and COO; Hani El Rayess, VP for Marketing; and Penn Batanov, Executive VP.

[hungryfeed max_items=”5″ template=”1″ url=”feed://feeds.finance.yahoo.com/rss/2.0/headline?s=VP&region=US&lang=en-US”]